The Australian National University (ANU) has begun a collaboration with the Korean Biotech Company MDimune Inc. to develop new and more effective treatments for Age-related Macular Degeneration (AMD).
AMD is one of the leading causes of blindness globally and is expected to affect 288 million people in 2040.
Assoc. Prof. Riccardo Natoli, Head of the ANU Clear Vision Research Lab and his team, which includes Adrian Cioanca PhD, and Yvette Wooff PhD, are working with MDimune to find AMD treatments.
Yvette Wooff said that, at the moment, there are no treatments available for the more prevalent form of AMD, they dry/geographic AMD, which affects around 90 percent of all AMD cases….